Spots Global Cancer Trial Database for Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
Official Title: A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors
Study ID: NCT00732420
Conditions
Study Description
Brief Summary: To determined what dose of topotecan can be safely given with daily pazopanib.
Detailed Description: A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Amsterdam, , Netherlands
GSK Investigational Site, Utrecht, , Netherlands
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
